Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Grants to USA, Canada, and International Researchers for Medical Research

Catalyst Award


GrantWatch ID#

Funding Source
Citizens United for Research in Epilepsy (CURE)
Array ( [0] => American Samoa (USA); [1] => Guam (USA); [2] => Puerto Rico (USA); [3] => Virgin Islands (USA); [4] => Northern Mariana Islands (USA); )

Geographic Focus
USA Territories: American Samoa (USA);   Guam (USA);   Puerto Rico (USA);   Virgin Islands (USA);   Northern Mariana Islands (USA);
USA Compact Free Associations:The Federated States of Micronesia (USA)   Marshall Islands (USA)   Republic of Palau (USA)
International, Israel and Canada.

Important Dates
LOI Date: 06/26/23
Deadline: 09/13/23 9:00 PM ET Save

Grant Description
Grants to USA, Canada, and International researchers at IHEs, research institutions, and biotechnology companies for medical research. Applicants must submit a letter of intent prior to submitting a full proposal. Funding is intended to support the development of innovative therapies and interventions for epilepsy.

CURE Epilepsy’s grant programs seek to accelerate promising research leading to new treatments and cures for people living with epilepsy. CURE prioritizes innovative projects that address its mission to cure epilepsy, affirming CURE's core belief that the only acceptable final goal is “no seizures, no side-effects.” 

CURE funds research that has the potential to truly transform and save lives. The purpose of this funding opportunity is to stimulate and accelerate discovery and development of new, transformative therapies for epilepsy, moving promising, well-supported preclinical and/or clinical research closer to clinical application. The award is intended to support nimble development of data necessary to attract larger commercialization funding opportunities and is not intended to replace those opportunities. Projects based on novel biological pathways and/or highly differentiated therapeutic approaches which are likely to have a high probability of success transitioning to clinical development are strongly encouraged.

Projects supported by this award mechanism should advance research to clinical trial readiness through development of biomarkers, optimization of new entities based on entities with established proof-of-concept including pharmacokinetics/pharmacodynamics, safety profiles and/or improved formulations, as well as studies that advance preclinical findings to pilot clinical trials. Proof-of-concept of the entity being developed is required.

Prospective pilot clinical trials where limited testing of a novel intervention is needed to inform the next step in the translational research may be considered. Priority areas include:

  • Innovative approaches that can prevent, modify and/or arrest the development of acquired epilepsy.
  • Development of novel approaches to prevent onset or halt the progression of severe pediatric epilepsies.
  • New, effective treatments for the >30% of the epilepsy population who are pharmaco-resistant.
  • Translational or clinical approaches aimed at normalizing sleep disturbances or circadian rhythms to treat seizures. 
  • New approaches, biomarkers or therapies to predict and prevent SUDEP.

Budgets may include salary support for the Principal Investigator (PI), technical staff and/or co-PIs, supplies, animal costs, vendor costs, limited equipment costs, and travel to an epilepsy-related conference only if the PI is presenting his/her CURE Epilepsy-funded research.


  • Others (see text field entitled "Additional Eligibility Criteria" for clarification)

Additional Eligibility Criteria
This award is available to independent researchers at or above the level of Assistant Professor (or equivalent) at universities and non-academic research institutions, including small biotechnology companies, that seek to develop new interventions for epilepsy. International applicants are welcome.

CURE Epilepsy encourages applications from groups identified as nationally underrepresented in the biomedical, clinical, behavioral, and social sciences. These groups include individuals with disabilities, veterans, persons from underrepresented racial and ethnic groups and gender diverse groups, women in biomedical-related disciplines, or any other characteristic protected by federal, state, or local law are encouraged to apply.

Postdoctoral fellows may not apply for this award.

The award is not intended to fund basic research on the mechanisms underlying epilepsy. Indirect costs are not supported.

Pre-Application Information
Funding Cycle:
- Open call for Letters of Intent: Tuesday, May 31st, 2022
- Letter of Intent deadline: Wednesday, June 29th, 2022, 9 PM ET
- Full proposal invitations: Friday, August 5th, 2022
- Full proposals due: Tuesday, September 13th, 2022, 9 PM ET
- Anticipated awardee notification: December 2022-January 2023
- Anticipated award start date: Spring 2023

All applicants must submit a Letter of Intent (LOI). Invited applicants should submit full proposals.

All materials must be submitted in English.

Grant Process:

Grant FAQs:

Estimated Size of Grant
Requests may be made for up to a maximum of $250,000. Awards of lesser amounts and shorter duration that will accomplish key milestones needed for clinical advancement are strongly encouraged. CURE Epilepsy reserves the right to fund only select specific aims or stage funding of proposals based on achievement of milestones.

Please note that there is a travel cap of $1,500 USD for international applicants and $1,000 USD for U.S. applicants per year, which can be budgeted for a maximum of 2 investigators (the PI and Co-PI).

Term of Contract
Requests may be made for funds paid over 2 years.

Contact Information
Submit an LOI online:

Questions regarding grant guidelines are welcome and should be directed to the Research Team at or 312-255-1801.

Cure Epilepsy
420 N. Wabash Avenue, Suite 650
Chicago, IL 60611
(312) 255-1801

Grant News
Live Chat Chat Now